Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: A current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke

Patrick Sulzgruber; Sven Wassmann; Anne Grete Semb; Wolfram Doehner; Petr Widimsky; Thomas Gremmel; Juan Carlos Kaski; Gianluigi Savarese; Giuseppe M.C. Rosano; Claudio Borghi; Keld Kjeldsen; Christian Torp-Pedersen; Thomas Andersen Schmidt; Basil S. Lewis; Heinz Drexel; Juan Tamargo; Dan Atar; Stefan Agewall; Alexander Niessner

doi:10.1093/ehjcvp/pvz016

Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA₂DS₂-VASc score of 1: A current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke

Patrick Sulzgruber, Sven Wassmann, Anne Grete Semb, Wolfram Doehner, Petr Widimsky, Thomas Gremmel, Juan Carlos Kaski, Gianluigi Savarese, Giuseppe M.C. Rosano, Claudio Borghi, Keld Kjeldsen, Christian Torp-Pedersen, Thomas Andersen Schmidt, Basil S. Lewis, Heinz Drexel, Juan Tamargo, Dan Atar, Stefan Agewall, Alexander Niessner^*

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Review › Forskning › peer review

Abstract

Oral anticoagulation in patients presenting with non-valvular atrial fibrillation and a CHA₂DS₂-VASc score of 1 (CHA₂DS₂-VASc of 2 in women) remains a challenging approach in clinical practice. Therapeutic decisions need to balance the individual benefit of reducing thromboembolic risk against the potential harm due to an increase in bleeding risk in this intermediate risk patient population. Within the current opinion statement of the European Society of Cardiology working group of cardiovascular pharmacotherapy and the European Society of Cardiology council on stroke the currently available evidence on the anti-thrombotic management in patients presenting with a CHA₂DS₂-VASc of 1 is summarized. Easily applicable tools for a personalized refinement of the individual thromboembolic risk in patients with atrial fibrillation and a CHA₂DS₂-VASc score of 1 that guide clinicians through the question whether to anticoagulate or not are provided.

Originalsprog	Engelsk
Artikelnummer	pvz016
Sider (fra-til)	171-180
Antal sider	10
Tidsskrift	European Heart Journal - Cardiovascular Pharmacotherapy
Vol/bind	5
Udgave nummer	3
DOI	https://doi.org/10.1093/ehjcvp/pvz016
Status	Udgivet - 1 jul. 2019
Udgivet eksternt	Ja

Adgang til dokumentet

10.1093/ehjcvp/pvz016

Andre filer og links

https://www.scopus.com/pages/publications/85068427343

Fingeraftryk

Udforsk hvilke forskningsemner 'Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA₂DS₂-VASc score of 1: A current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke' indeholder.

Citationsformater

Sulzgruber, P., Wassmann, S., Semb, A. G., Doehner, W., Widimsky, P., Gremmel, T., Kaski, J. C., Savarese, G., Rosano, G. M. C., Borghi, C., Kjeldsen, K., Torp-Pedersen, C., Schmidt, T. A., Lewis, B. S., Drexel, H., Tamargo, J., Atar, D., Agewall, S., & Niessner, A. (2019). Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA₂DS₂-VASc score of 1: A current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. European Heart Journal - Cardiovascular Pharmacotherapy, 5(3), 171-180. Artikel pvz016. https://doi.org/10.1093/ehjcvp/pvz016

Sulzgruber, Patrick ; Wassmann, Sven ; Semb, Anne Grete et al. / Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA₂DS₂-VASc score of 1 : A current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. I: European Heart Journal - Cardiovascular Pharmacotherapy. 2019 ; Bind 5, Nr. 3. s. 171-180.

@article{b0b5c7b4c4574a19837bb9bb89d68ad2,

title = "Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: A current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke",

abstract = "Oral anticoagulation in patients presenting with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 (CHA2DS2-VASc of 2 in women) remains a challenging approach in clinical practice. Therapeutic decisions need to balance the individual benefit of reducing thromboembolic risk against the potential harm due to an increase in bleeding risk in this intermediate risk patient population. Within the current opinion statement of the European Society of Cardiology working group of cardiovascular pharmacotherapy and the European Society of Cardiology council on stroke the currently available evidence on the anti-thrombotic management in patients presenting with a CHA2DS2-VASc of 1 is summarized. Easily applicable tools for a personalized refinement of the individual thromboembolic risk in patients with atrial fibrillation and a CHA2DS2-VASc score of 1 that guide clinicians through the question whether to anticoagulate or not are provided.",

keywords = "Anticoagulation, Atrial fibrillation, CHADS-VASc score, Intermediate risk, Stroke/diagnosis, Risk Assessment, Administration, Oral, Humans, Risk Factors, Decision Support Techniques, Treatment Outcome, Consensus, Hemorrhage/chemically induced, Anticoagulants/administration \& dosage, Clinical Decision-Making, Atrial Fibrillation/diagnosis, CHA(2)DS(2)-VASc score",

author = "Patrick Sulzgruber and Sven Wassmann and Semb, \{Anne Grete\} and Wolfram Doehner and Petr Widimsky and Thomas Gremmel and Kaski, \{Juan Carlos\} and Gianluigi Savarese and Rosano, \{Giuseppe M.C.\} and Claudio Borghi and Keld Kjeldsen and Christian Torp-Pedersen and Schmidt, \{Thomas Andersen\} and Lewis, \{Basil S.\} and Heinz Drexel and Juan Tamargo and Dan Atar and Stefan Agewall and Alexander Niessner",

year = "2019",

month = jul,

day = "1",

doi = "10.1093/ehjcvp/pvz016",

language = "English",

volume = "5",

pages = "171--180",

journal = "European Heart Journal - Cardiovascular Pharmacotherapy",

issn = "2055-6837",

publisher = "Oxford University Press",

number = "3",

}

Sulzgruber, P, Wassmann, S, Semb, AG, Doehner, W, Widimsky, P, Gremmel, T, Kaski, JC, Savarese, G, Rosano, GMC, Borghi, C, Kjeldsen, K, Torp-Pedersen, C, Schmidt, TA, Lewis, BS, Drexel, H, Tamargo, J, Atar, D, Agewall, S & Niessner, A 2019, 'Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA₂DS₂-VASc score of 1: A current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke', European Heart Journal - Cardiovascular Pharmacotherapy, bind 5, nr. 3, pvz016, s. 171-180. https://doi.org/10.1093/ehjcvp/pvz016

Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA₂DS₂-VASc score of 1: A current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. / Sulzgruber, Patrick; Wassmann, Sven; Semb, Anne Grete et al.
I: European Heart Journal - Cardiovascular Pharmacotherapy, Bind 5, Nr. 3, pvz016, 01.07.2019, s. 171-180.

Publikation: Bidrag til tidsskrift › Review › Forskning › peer review

TY - JOUR

T1 - Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1

T2 - A current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke

AU - Sulzgruber, Patrick

AU - Wassmann, Sven

AU - Semb, Anne Grete

AU - Doehner, Wolfram

AU - Widimsky, Petr

AU - Gremmel, Thomas

AU - Kaski, Juan Carlos

AU - Savarese, Gianluigi

AU - Rosano, Giuseppe M.C.

AU - Borghi, Claudio

AU - Kjeldsen, Keld

AU - Torp-Pedersen, Christian

AU - Schmidt, Thomas Andersen

AU - Lewis, Basil S.

AU - Drexel, Heinz

AU - Tamargo, Juan

AU - Atar, Dan

AU - Agewall, Stefan

AU - Niessner, Alexander

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Oral anticoagulation in patients presenting with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 (CHA2DS2-VASc of 2 in women) remains a challenging approach in clinical practice. Therapeutic decisions need to balance the individual benefit of reducing thromboembolic risk against the potential harm due to an increase in bleeding risk in this intermediate risk patient population. Within the current opinion statement of the European Society of Cardiology working group of cardiovascular pharmacotherapy and the European Society of Cardiology council on stroke the currently available evidence on the anti-thrombotic management in patients presenting with a CHA2DS2-VASc of 1 is summarized. Easily applicable tools for a personalized refinement of the individual thromboembolic risk in patients with atrial fibrillation and a CHA2DS2-VASc score of 1 that guide clinicians through the question whether to anticoagulate or not are provided.

AB - Oral anticoagulation in patients presenting with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 (CHA2DS2-VASc of 2 in women) remains a challenging approach in clinical practice. Therapeutic decisions need to balance the individual benefit of reducing thromboembolic risk against the potential harm due to an increase in bleeding risk in this intermediate risk patient population. Within the current opinion statement of the European Society of Cardiology working group of cardiovascular pharmacotherapy and the European Society of Cardiology council on stroke the currently available evidence on the anti-thrombotic management in patients presenting with a CHA2DS2-VASc of 1 is summarized. Easily applicable tools for a personalized refinement of the individual thromboembolic risk in patients with atrial fibrillation and a CHA2DS2-VASc score of 1 that guide clinicians through the question whether to anticoagulate or not are provided.

KW - Anticoagulation

KW - Atrial fibrillation

KW - CHADS-VASc score

KW - Intermediate risk

KW - Stroke/diagnosis

KW - Risk Assessment

KW - Administration, Oral

KW - Humans

KW - Risk Factors

KW - Decision Support Techniques

KW - Treatment Outcome

KW - Consensus

KW - Hemorrhage/chemically induced

KW - Anticoagulants/administration & dosage

KW - Clinical Decision-Making

KW - Atrial Fibrillation/diagnosis

KW - CHA(2)DS(2)-VASc score

UR - https://www.scopus.com/pages/publications/85068427343

U2 - 10.1093/ehjcvp/pvz016

DO - 10.1093/ehjcvp/pvz016

M3 - Review

C2 - 31119266

AN - SCOPUS:85068427343

SN - 2055-6837

VL - 5

SP - 171

EP - 180

JO - European Heart Journal - Cardiovascular Pharmacotherapy

JF - European Heart Journal - Cardiovascular Pharmacotherapy

IS - 3

M1 - pvz016

ER -

Sulzgruber P, Wassmann S, Semb AG, Doehner W, Widimsky P, Gremmel T et al. Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA₂DS₂-VASc score of 1: A current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. European Heart Journal - Cardiovascular Pharmacotherapy. 2019 jul. 1;5(3):171-180. pvz016. doi: 10.1093/ehjcvp/pvz016